Indication
Mouth infection prevention
Mouth infection prevention refers to clinical prophylaxis aimed at inhibiting bacterial, fungal, or viral colonization and invasion within the tissues of the oral cavity. Read more about Mouth infection prevention
25 drugs 23 manufacturers
Drugs that treat it
Common Mouth infection prevention therapies.
CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE
PERIDEX (chlorhexidine gluconate)
CHLORHEXIDINE GLUCONATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMouth infection prevention refers to clinical prophylaxis aimed at inhibiting bacterial, fungal, or viral colonization and invasion within the tissues of the oral cavity.
This preventative objective primarily targets populations vulnerable to compromised mucosal integrity or immune defenses, such as patients undergoing cytotoxic chemotherapy, head and neck radiotherapy, or immunosuppressive therapy, as well as individuals with severe xerostomia or indwelling oral appliances.
Pathophysiologically, disruption of salivary flow, epithelial barrier breakdown from mucositis, or systemic neutropenia permits opportunistic pathogens—most commonly *Candida* species, oral streptococci, or herpes simplex virus—to proliferate locally or translocate into the bloodstream.
Clinical management focuses on reducing microbial bioburden and preserving intact mucosal barriers to forestall localized ulceration, pain, and life-threatening systemic bacteremia or sepsis.
- nih.gov
Mouth infection prevention refers to clinical prophylaxis aimed at inhibiting bacterial, fungal, or viral colonization and invasion within the tissues of the oral cavity This preventative objective primarily targets populations vulnerable to compromised mucosal integrity or immune defenses, such as patients undergoing cytotoxic chemotherapy, head and neck radiotherapy, or immunosuppressive therapy, as well as individuals with severe xerostomia or indwelling oral appliances Pathophysiologically, ...
- cancer.gov
This preventative objective primarily targets populations vulnerable to compromised mucosal integrity or immune defenses, such as patients undergoing cytotoxic chemotherapy, head and neck radiotherapy, or immunosuppressive therapy, as well as individuals with severe xerostomia or indwelling oral appliances
- nih.gov
This preventative objective primarily targets populations vulnerable to compromised mucosal integrity or immune defenses, such as patients undergoing cytotoxic chemotherapy, head and neck radiotherapy, or immunosuppressive therapy, as well as individuals with severe xerostomia or indwelling oral appliances
- nih.gov
Pathophysiologically, disruption of salivary flow, epithelial barrier breakdown from mucositis, or systemic neutropenia permits opportunistic pathogens—most commonly *Candida* species, oral streptococci, or herpes simplex virus—to proliferate locally or translocate into the bloodstream
- nih.gov
Clinical management focuses on reducing microbial bioburden and preserving intact mucosal barriers to forestall localized ulceration, pain, and life-threatening systemic bacteremia or sepsis
Personalize your experience
Follow Mouth infection prevention and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.